top of page

Allurion balloon results in 22.1% weight loss at one year

Allurion Technologies has revealed data from a study of 121 patients across 11 obesity centres treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. The outcomes were presented at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) 2024. In comparison, studies show that patients treated with 12-month endoscopic intragastric balloons achieve 15.4% and 16.2% total body weight loss (not compared in head-to-head studies with any other gastric balloons).


“We believe these findings underscore the potential of the Allurion Balloon to deliver superior outcomes to other intragastric balloons, approaching those of weight loss surgery, for patients seeking effective and safe weight loss solutions,” said Dr Shantanu Gaur, Founder and CEO of Allurion.

Evidence from multiple studies indicates that the Allurion Balloon - a procedureless, liquid-filled balloon - has a significantly lower intolerance rate compared to 12-month endoscopic balloons (1-3% vs 14.4%)5, with an overall serious adverse event rate that averages 10 times less than other liquid-filled balloons (not compared in head-to-head studies with any other gastric balloons).


Presentations also include data from a study analysing 1,313 conversations from patients across 26 bariatric clinics in 12 countries and Coach Iris – Allurion’s AI-powered weight loss coach – assessing the safety, accuracy, and overall quality of a beta version released in 2023.

Conversations between patients and Coach Iris were reviewed against a unique framework developed in-house and recently presented at IFSO-EC. Named “FAST,” this framework is designed to evaluate and monitor the Fidelity, Accuracy, Safety, and Tone of Coach Iris. The text-based, human-like messaging received satisfaction scores of  84% on Fidelity, 79% on Accuracy, 89% on Safety, and 95% on Tone.

Presentations at ASMBS also include data on the impact of digital appetite tracking and eating behaviours in Allurion Balloon Program patients.


bottom of page